RT Journal Article
SR Electronic
T1 RISK6, a universal 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19006197
DO 10.1101/19006197
A1 Penn-Nicholson, Adam
A1 Mbandi, Stanley Kimbung
A1 Thompson, Ethan
A1 Mendelsohn, Simon C.
A1 Suliman, Sara
A1 Chegou, Novel N.
A1 Malherbe, Stephanus T.
A1 Darboe, Fatoumatta
A1 Erasmus, Mzwandile
A1 Hanekom, Willem A.
A1 Bilek, Nicole
A1 Fisher, Michelle
A1 Kaufmann, Stefan H. E.
A1 Winter, Jill
A1 Murphy, Melissa
A1 Wood, Robin
A1 Morrow, Carl
A1 Van Rhijn, Ildiko
A1 Moody, Branch
A1 Murray, Megan
A1 Andrade, Bruno B.
A1 Sterling, Timothy R.
A1 Sutherland, Jayne
A1 Naidoo, Kogieleum
A1 Padayatchi, Nesri
A1 Walzl, Gerhard
A1 Hatherill, Mark
A1 Zak, Daniel
A1 Scriba, Thomas J.
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
A1 ,
YR 2019
UL http://medrxiv.org/content/early/2019/09/09/19006197.abstract
AB Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts.Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with lung immunopathology activity, measured by positron emission tomography, and tracked treatment response, demonstrating utility as treatment response biomarker, while predicting treatment failure prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field studies.Competing Interest StatementAPN, ET, WAH, DZ and TJS are co-inventors of a patent on RISK6. All other authors declare no competing interests.Clinical TrialThis study analyzed specimens from a previously conducted clinical trial, IMPRESS (clinicaltrials.gov NTC02114684), and seven observational studies.Funding StatementSupport for this study was provided by the Bill and Melinda Gates Foundation (grants OPP1023483, OPP1065330, and Grand Challenges in Global Health (GC6-74 grant 37772)) and the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research Council with funds received from the South African Department of Science and Technology. The ACS study was also supported by BMGF GC12 (grant 37885) for QuantiFERON testing. The IMPRESS trial was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP: TA.2011.40200.044), and by Bayer Healthcare (moxifloxacin donation). The AE-TBC and ScreenTB projects were funded by the EDCTP with grant numbers IP_2009_32040 and DRIA2014-311 respectively. RePORT Brazil is supported by the Departamento de Ciência e Tecnologia (DECIT) - Secretaria de Ciência e Tecnologia (SCTIE) – Ministério da Saúde (MS), Brazil [25029.000507/2013-07] the National Institutes of Allergy and Infectious Diseases [U01-AI069923], and CRDF Global [DAA3-18-64151, DAA3-18-64152 and DAA3-18-64153]. Work in Peru was supported by the Tuberculosis Research Unit Network (U19 AI111224). SCM received training in research that was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW010559. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. F.D. was supported by the Margaret McNamara educational grant for women in developing countries. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe RISK6 scores and associated clinical data for all cohorts are in Supplementary Tables 5-13. https://bitbucket.org/satvi/risk6